Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery

[1]  C. Pritchard,et al.  Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery , 2020, British Journal of Cancer.

[2]  C. Ireson,et al.  The role of mouse tumour models in the discovery and development of anticancer drugs , 2019, British Journal of Cancer.

[3]  D. Ingber,et al.  Modelling cancer in microfluidic human organs-on-chips , 2019, Nature Reviews Cancer.

[4]  F. Bertolini.  Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors , 2018, British Journal of Cancer.

[5]  E. Liu,et al.  Mouse Models for Cancer Immunotherapy Research. , 2018, Cancer discovery.

[6]  Jakob Nikolas Kather,et al.  Topography of cancer-associated immune cells in human solid tumors , 2018, eLife.

[7]  G. Raj,et al.  Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. , 2018, European urology oncology.

[8]  Jason S. Carroll,et al.  A patient‐derived explant (PDE) model of hormone‐dependent cancer , 2018, Molecular oncology.

[9]  H. Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[10]  D. Lynn,et al.  Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants * , 2018, Molecular & Cellular Proteomics.

[11]  A. Aguilar-Lemarroy,et al.  Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment , 2018, Technology in cancer research & treatment.

[12]  J. Takagi,et al.  Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. , 2018, Cell stem cell.

[13]  Andrea Sottoriva,et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.

[14]  Clare Verrill,et al.  Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project , 2018, Genetics in Medicine.

[15]  U. McDermott,et al.  Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells , 2018, eLife.

[16]  Hans Clevers,et al.  A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.

[17]  J. Wu,et al.  Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. , 2017, Oncology letters.

[18]  J. Banchereau,et al.  Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Hellmut G. Augustin,et al.  Preclinical mouse solid tumour models: status quo, challenges and perspectives , 2017, Nature Reviews Cancer.

[20]  I. Wistuba,et al.  Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues , 2017, Scientific Reports.

[21]  M. Hidalgo,et al.  Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  N. Takakura,et al.  Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy , 2017, Scientific Reports.

[23]  Seung‐Mo Hong,et al.  Prediction of radio-responsiveness with immune-profiling in patients with rectal cancer , 2017, Oncotarget.

[24]  C. Janfelt,et al.  Combination of MALDI-MSI and cassette dosing for evaluation of drug distribution in human skin explant , 2017, Analytical and Bioanalytical Chemistry.

[25]  Peng Li,et al.  Current status and perspectives of patient-derived xenograft models in cancer research , 2017, Journal of Hematology & Oncology.

[26]  Miles A. Miller,et al.  In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.

[27]  S. Thiyagarajan,et al.  Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2 , 2017, Scientific Reports.

[28]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[29]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[30]  D. Moore,et al.  Ex Vivo Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. , 2017, Cancer research.

[31]  P. Majumder,et al.  CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer , 2017, Cellular Oncology.

[32]  Hans Clevers,et al.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer , 2017, The Journal of experimental medicine.

[33]  U. Demirci,et al.  Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow , 2016, Scientific Reports.

[34]  Hans Clevers,et al.  Designer matrices for intestinal stem cell and organoid culture , 2016, Nature.

[35]  M. Heikenwalder,et al.  Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. , 2016, Blood.

[36]  Laurence Zitvogel,et al.  Mouse models in oncoimmunology , 2016, Nature Reviews Cancer.

[37]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[38]  L. Shultz,et al.  Improved B cell development in humanized NOD‐scid IL2Rγnull mice transgenically expressing human stem cell factor, granulocyte‐macrophage colony‐stimulating factor and interleukin‐3 , 2016, Immunity, inflammation and disease.

[39]  Toshio Uraoka,et al.  A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. , 2016, Cell stem cell.

[40]  Yoon-La Choi,et al.  Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples , 2015, PloS one.

[41]  I. Tannock,et al.  Failures in Phase III: Causes and Consequences , 2015, Clinical Cancer Research.

[42]  Hans Clevers,et al.  Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases , 2015, Proceedings of the National Academy of Sciences.

[43]  L. Howells,et al.  Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice , 2015, Science Translational Medicine.

[44]  D. Proia,et al.  Resistance to HSP90 inhibition involving loss of MCL1 addiction , 2015, Oncogene.

[45]  Rory Stark,et al.  Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.

[46]  R. W. Hansen,et al.  The cost of drug development. , 2015, The New England journal of medicine.

[47]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[48]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[49]  Harikrishna Narasimhan,et al.  Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity , 2015, Nature Communications.

[50]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[51]  C. Unger,et al.  Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. , 2014, Advanced drug delivery reviews.

[52]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[53]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[54]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[55]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[56]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[57]  R. Nolley,et al.  Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate , 2013, Laboratory Investigation.

[58]  Karen E. Knudsen,et al.  Ex vivo culture of human prostate tissue and drug development , 2013, Nature Reviews Urology.

[59]  I. Tannock,et al.  Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept , 2013, Clinical Cancer Research.

[60]  Andrew D J Pearson,et al.  How can attrition rates be reduced in cancer drug discovery? , 2013, Expert opinion on drug discovery.

[61]  A. Chinnaiyan,et al.  Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.

[62]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[63]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[64]  H. Scher,et al.  Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors , 2012, Clinical Cancer Research.

[65]  Jianzhu Chen,et al.  Engineering humanized mice for improved hematopoietic reconstitution , 2012, Cellular and Molecular Immunology.

[66]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[67]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[68]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[69]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[70]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[71]  M. Hidalgo,et al.  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[72]  Ian F Tannock,et al.  When are "positive" clinical trials in oncology truly positive? , 2011, Journal of the National Cancer Institute.

[73]  M. MacFarlane,et al.  A TRAIL-R1-specific ligand in combination with doxorubicin selectively targets primary breast tumour cells for apoptosis , 2010, Breast Cancer Research.

[74]  Saumyadipta Pyne,et al.  Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors , 2010, Proceedings of the National Academy of Sciences.

[75]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[76]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[77]  D. Greiner,et al.  Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex , 2009, Clinical and experimental immunology.

[78]  T. Yoshimasu,et al.  Histoculture drug response assay for gefitinib in non-small-cell lung cancer , 2009, General thoracic and cardiovascular surgery.

[79]  G. Cohen,et al.  Barriers to effective TRAIL-targeted therapy of malignancy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Eva Mezey,et al.  Simultaneous Visualization of Multiple Antigens with Tyramide Signal Amplification using Antibodies from the same Species , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[81]  T. Yoshimasu,et al.  Data acquisition for the histoculture drug response assay in lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.

[82]  M. Hotz,et al.  Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. , 2006, Anticancer research.

[83]  T. Yoshimasu,et al.  [Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer]. , 2005, Gan to kagaku ryoho. Cancer & chemotherapy.

[84]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[85]  P. Ma,et al.  Oncology's trials , 2003, Nature Reviews Drug Discovery.

[86]  T. Yoshimasu,et al.  [Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer]. , 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

[87]  Robert F. Bonner,et al.  Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.

[88]  É. Mezey,et al.  Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[89]  R. Hoffman,et al.  Clinical applications of the histoculture drug response assay. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  R. Hoffman,et al.  Correlation of drug response in human tumors histocultured in vitro with an image-analysis MTT end point and in vivo xenografted in nude mice. , 1992, Anticancer Research.

[91]  R. Hoffman,et al.  Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[92]  T. Harris,et al.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. , 1989, Journal of immunological methods.

[93]  C. Redfern,et al.  In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Hoffman,et al.  In vivo-like growth of human tumors in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[95]  J. Leighton,et al.  The similarity in histologic appearance of some human cancer and normal cell strains in sponge-matrix tissue culture. , 1957, Cancer research.

[96]  J. Leighton.  The growth patterns of some transplantable animal tumors in sponge matrix tissue culture. , 1954, Journal of the National Cancer Institute.

[97]  J. Leighton.  A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. , 1951, Journal of the National Cancer Institute.

[98]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[99]  R. Hoffman.  3D Sponge-Matrix Histoculture: An Overview. , 2018, Methods in molecular biology.

[100]  J. L. Quesne,et al.  Resistance to HSP90 inhibition involving loss of MCL1 addiction , 2015, Oncogene.

[101]  C. Caldas,et al.  Progesterone receptor modulates ERa action in breast cancer , 2015 .

[102]  R. Burgemeister.  Laser capture microdissection of FFPE tissue sections bridging the gap between microscopy and molecular analysis. , 2011, Methods in molecular biology.

[103]  F. Gejyo,et al.  Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. , 2009, Internal medicine.

[104]  S. Moriyama,et al.  [The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer]. , 2008, Kyobu geka. The Japanese journal of thoracic surgery.

[105]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[106]  F. Welch,et al.  Causes and Consequences , 2017, Nature.